TENDER MOMENTS
- Manufacturer
- JAFRA COSMETICS INTERNATIONAL | Jafra Manufacturing, S.A. de C.V.
- Effective date
- 2012-05-16
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-05-31 22:31:53
Label at a glance#
Label contents#
Full prescribing information#
OTC - PURPOSE SECTION
PURPOSE: SUNSCREEN
INACTIVE INGREDIENT SECTION
OTHER INGREDIENTS: WATER/AQUA, ALUMINA, DIMETHICONE, SODIUM DIHYDROXYCETYL PHOSPHATE, GLYCERYL STEARATE SE, ADIPIC ACID/DIETHYLENE GLYCOL/GLYCERIN CROSSPOLYMER, PVP/EICOSENE COPOLYMER, AVENA SATIVA (OAT) KERNEL EXTRACT, PANTHENOL, TOCOPHERYL ACETATE, BUTYLENE GLYCOL, CETYL ALCOHOL, XANTHAN GUM, FRAGRANCE/PARFUM, DMDM HYDANTOIN, PEG-4 LAURATE, IODOPROPYNYL BUTYLCARBAMATE, TRISODIUM EDTA, [FRAGRANCE/PARFUM CONTAINS: CITRONELLOL, GERANIOL, HEXYL CINNAMAL, HYDROXYCITRONELLOL, BUTYLPHENYL METHYLPROPIONAL (LILLIAL), LINALOL, ALPHA-ISOMMETHYL IONONE]
INDICATIONS & USAGE SECTION
BABY BLOCK SPF 45
DOSAGE & ADMINISTRATION SECTION
APPLY WATER-RESISTANT SUNSCREEN 20 MINUTES BEFORE SUN EXPOSURE.
OTC - STOP USE SECTION
DISCONTINUE USE IF SIGNS OF IRRITATION APPEAR.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
WARNINGS SECTION
WARNINGS: FOR EXTERNAL USE ONLY. AVOID CONTACT WITH EYES.
PEDIATRIC USE SECTION
SEEK THE ADVICE OF A PHYSICIAN PRIOR TO USE ON CHILDREN UNDER 6 MONTHS OF AGE.
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68828-060-13 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-c310-f424-e053-dadaa90a57ce | TENDER MOMENTS SPF 45 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68828-060-13 | TENDER MOMENTSSPF 45 | 50 mL in 1 TUBE | LOTION | 50 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 68828-060 | TENDER MOMENTS SPF 45 (HOMOSALATE OCTINOXATE OCTISALATE OXYBENZONE TITANIUM DIOXIDE OCTOCRYLENE) LOTION [JAFRA COSMETICS INTERNATIONAL] | 1 | Legacy NDC, 1 package rows | 20120517_537296b2-3782-4081-98b2-483e8aaf8b6e.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| HOMOSALATE | ACTIVE INGREDIENT | V06SV4M95S | 1 | |
| OCTINOXATE | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| OCTISALATE | ACTIVE INGREDIENT | 4X49Y0596W | 1 | |
| OCTOCRYLENE | ACTIVE INGREDIENT | 5A68WGF6WM | 1 | |
| OXYBENZONE | ACTIVE INGREDIENT | 95OOS7VE0Y | 1 | |
| TITANIUM DIOXIDE | ACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| HOMOSALATE | ACTIVE MOIETY | V06SV4M95S | 1 | |
| OCTINOXATE | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| OCTISALATE | ACTIVE MOIETY | 4X49Y0596W | 1 | |
| OCTOCRYLENE | ACTIVE MOIETY | 5A68WGF6WM | 1 | |
| OXYBENZONE | ACTIVE MOIETY | 95OOS7VE0Y | 1 | |
| TITANIUM DIOXIDE | ACTIVE MOIETY | 15FIX9V2JP | 1 | |
| .ALPHA.-TOCOPHEROL ACETATE | INACTIVE INGREDIENT | 9E8X80D2L0 | 1 | |
| ALUMINUM OXIDE | INACTIVE INGREDIENT | LMI26O6933 | 1 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| CETYL ALCOHOL | INACTIVE INGREDIENT | 936JST6JCN | 1 | |
| DIETHYLENE GLYCOL ADIPATE | INACTIVE INGREDIENT | 6KE5V549E0 | 1 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| DMDM HYDANTOIN | INACTIVE INGREDIENT | BYR0546TOW | 1 | |
| EDETATE TRISODIUM | INACTIVE INGREDIENT | 420IP921MB | 1 | |
| GLYCERYL STEARATE SE | INACTIVE INGREDIENT | FCZ5MH785I | 1 | |
| IODOPROPYNYL BUTYLCARBAMATE | INACTIVE INGREDIENT | 603P14DHEB | 1 | |
| OAT | INACTIVE INGREDIENT | Z6J799EAJK | 1 | |
| PANTHENOL | INACTIVE INGREDIENT | WV9CM0O67Z | 1 | |
| PEG-4 LAURATE | INACTIVE INGREDIENT | AYF4VM3N1Z | 1 | |
| POVIDONE K30 | INACTIVE INGREDIENT | U725QWY32X | 1 | |
| SODIUM PHOSPHATE, MONOBASIC | INACTIVE INGREDIENT | 3980JIH2SW | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| XANTHAN GUM | INACTIVE INGREDIENT | TTV12P4NEE | 1 |
Products#
Every source-derived product name is available through these pages.
- TENDER MOMENTS SPF 45
- HOMOSALATE OCTINOXATE OCTISALATE OXYBENZONE TITANIUM DIOXIDE OCTOCRYLENE
- WATER
- ALUMINUM OXIDE
- DIMETHICONE
- GLYCERYL STEARATE SE
- SODIUM PHOSPHATE, MONOBASIC
- BUTYLENE GLYCOL
- DIETHYLENE GLYCOL ADIPATE
- OAT
- POVIDONE K30
- CETYL ALCOHOL
- PEG-4 LAURATE
- DMDM HYDANTOIN
- IODOPROPYNYL BUTYLCARBAMATE
- PANTHENOL
- .ALPHA.-TOCOPHEROL ACETATE
- XANTHAN GUM
- EDETATE TRISODIUM
- HOMOSALATE
- OCTINOXATE
- OCTISALATE
- OCTOCRYLENE
- TITANIUM DIOXIDE
- OXYBENZONE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68828-060 | 68828-060-13 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERYL STEARATE SE | GLYCERYL STEARATE SE | FCZ5MH785I | CREAM / TOPICAL | 4 %w/w | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TROCHE / ORAL | 948 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SUSPENSION / TOPICAL | 0.11 %w/v | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SOLUTION / ORAL | 25 mg/5ml | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, EXTENDED RELEASE / ORAL | 132 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | SUSPENSION / OPHTHALMIC | 14 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, DELAYED RELEASE / ORAL | 516 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | SOLUTION/ DROPS / OPHTHALMIC | 4 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | LOTION / TOPICAL | 1140 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION / INTRAMUSCULAR | 161 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TROCHE / ORAL | 175 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | POWDER, FOR SUSPENSION / ORAL | 257 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SUSPENSION/ DROPS / ORAL | 22 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | LOZENGE / ORAL | 700 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | AEROSOL, FOAM / TOPICAL | 1.9 %w/w | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, EXTENDED RELEASE / ORAL | 368 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SOLUTION / OPHTHALMIC | 0.6 %w/v | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | TABLET / ORAL | 2 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | ENEMA / RECTAL | 150 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | SYSTEM / TOPICAL | 14.2 mg | ||
| .ALPHA.-TOCOPHEROL ACETATE | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | TABLET / ORAL | 0.5 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET / SUBLINGUAL | 30 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, DELAYED RELEASE PARTICLES / ORAL | 70 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL, FOAM / VAGINAL | 0.75 %w/w | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | LOZENGE / ORAL | 1264 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | FILM / SUBLINGUAL | 7 mg | ||
| ALUMINUM OXIDE | ALUMINUM OXIDE | LMI26O6933 | SPONGE / TOPICAL | NA | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | SUSPENSION / TOPICAL | 2.01 %w/w | ||
| BUTYLENE GLYCOL | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TOPICAL | 1400 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET / ORAL | 56 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | GRANULE, FOR SUSPENSION / ORAL | 120 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | LOTION / TOPICAL | 0.3 %w/v | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, CHEWABLE / ORAL | 245 mg | ||
| SODIUM PHOSPHATE, MONOBASIC | SODIUM PHOSPHATE, MONOBASIC | 3980JIH2SW | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 13.2 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL, FOAM / RECTAL | 17 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | GEL / TOPICAL | 58 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET / ORAL | 2828 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | INJECTION / INTRAMUSCULAR | 0.59 %w/v | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, ORALLY DISINTEGRATING / ORAL | 0.15 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, COATED / ORAL | 0.25 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET, FOR SUSPENSION / ORAL | 462 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | CAPSULE / ORAL | 540 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 2350 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | POWDER, FOR SOLUTION / ORAL | 2832 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | TABLET, FILM COATED / ORAL | 0.08 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | POWDER / ORAL | 275 mg | ||
| EDETATE TRISODIUM | EDETATE TRISODIUM | 420IP921MB | CREAM / TOPICAL | NA | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | AEROSOL / TOPICAL | 1.16 %w/w | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | POWDER, FOR SUSPENSION / ORAL | 600 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, ORALLY DISINTEGRATING / ORAL | 9 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | SUSPENSION / RECTAL | 452 mg | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | SOLUTION / OPHTHALMIC | 42 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 59 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | SUSPENSION / OPHTHALMIC | 0.5 %w/v | ||
| POVIDONE K30 | POVIDONE K30 | U725QWY32X | TABLET / BUCCAL | 1 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | CAPSULE, DELAYED RELEASE / ORAL | 59 mg | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | POWDER, FOR SOLUTION / ORAL | 10 mg/5ml | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | CREAM / TOPICAL | 1280 mg | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | SUSPENSION / AURICULAR (OTIC) | 1 %w/v | ||
| GLYCERYL STEARATE SE | GLYCERYL STEARATE SE | FCZ5MH785I | LOTION / TOPICAL | 46 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 714465bd-2186-4e99-9fb7-4eb6c509b56e | 537296b2-3782-4081-98b2-483e8aaf8b6e | 2012-05-16 | Warnings | 714465bd-2186-4e99-9fb7-4eb6c509b56e 537296b2-3782-4081-98b2-483e8aaf8b6e |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.

